

--38. A method as defined in claim 37, wherein said GLP-1 agonist is selected from the group consisting of Arg<sup>26</sup>, Lys<sup>34</sup>(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), Arg<sup>34</sup>, Lys<sup>26</sup>(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), exendin-3, exendin-4, Val<sup>8</sup>-GLP-1(7-37), Thr<sup>8</sup>-GLP-1(7-37), Met<sup>8</sup>-GLP-1(7-37), and Gly<sup>8</sup>-GLP-1(7-37).--

--39. A method as defined in claim 37, wherein said GLP-1 agonist binds to a GLP-1 receptor with an affinity constant (Kd) below 1 μM.--

--40. A method for reducing the serum level of lipoprotein A (Ip(A)) and/or apolipoprotein A (apo(A)) in a patient in need of such treatment, said method comprising administering to said patient a GLP-1 agonist in an amount effective for said reduction.--

--41. A method as defined in claim 40, wherein said GLP-1 agonist is selected from the group consisting of Arg<sup>26</sup>, Lys<sup>34</sup>(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), Arg<sup>34</sup>, Lys<sup>26</sup>(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37), exendin-3, exendin-4, Val<sup>8</sup>-GLP-1(7-37), Thr<sup>8</sup>-GLP-1(7-37), Met<sup>8</sup>-GLP-1(7-37), and Gly<sup>8</sup>-GLP-1(7-37).--

42  
--41. A method as defined in claim 40, wherein said GLP-1 agonist binds to a GLP-1 receptor with an affinity constant (Kd) below 1 μM.--

#### REMARKS

Entry of this amendment is respectfully requested.


In this amendment, original claims 1-25 are cancelled and new claims 26-41 are presented. Support for the new claims can be found in the specification and original claims. No new matter is added. Accordingly, claims 26-41 are pending and at issue.

This application contains a Sequence Listing. Applicants enclose a 3.5" floppy disk containing the Sequence Listing. The content of the attached paper entitled "SEQUENCE LISTING" and of the accompanying identically labelled diskette is the same.

It is believed that the claims are in condition for allowance, and a determination to that effect is earnestly solicited.

Respectfully submitted,

Date: March 7, 2001



Reza Green, Reg. No. 38,475  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



23650

PATENT TRADEMARK OFFICE